Next Article in Journal
A Scalable Manufacturing Approach to Single Dose Vaccination against HPV
Next Article in Special Issue
Development of mRNA Vaccines: Scientific and Regulatory Issues
Previous Article in Journal
Tumor-Infiltrating Lymphoid Cells in Colorectal Cancer Patients with Varying Disease Stages and Microsatellite Instability-High/Stable Tumors
Previous Article in Special Issue
Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans
Open AccessReview

Nanomaterial Delivery Systems for mRNA Vaccines

1
Department of Bioengineering, George Mason University, 4400 University Drive, MS 1J7, Fairfax, VA 22030, USA
2
Department of Chemistry & Biochemistry, George Mason University, 4400 University Drive, Fairfax, VA 22030, USA
3
Perelman School of Medicine, University of Pennsylvania, 130 Stemmler Hall, 3450 Hamilton Walk, Philadelphia, PA 19104, USA
4
Perelman School of Medicine, University of Pennsylvania, 410B Hill Pavilion, 380 S. University Ave, Philadelphia, PA 19104, USA
*
Author to whom correspondence should be addressed.
Vaccines 2021, 9(1), 65; https://doi.org/10.3390/vaccines9010065
Received: 27 December 2020 / Revised: 11 January 2021 / Accepted: 14 January 2021 / Published: 19 January 2021
(This article belongs to the Special Issue The Past, Present, and Future of mRNA Vaccines)
The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the development of lipid nanoparticle delivery systems that not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play roles as adjuvants and in vaccine reactogenicity. We present an overview of mRNA delivery systems and then focus on the lipid nanoparticles used in the current SARS-CoV-2 vaccine clinical trials. The review concludes with an analysis of the determinants of the performance of lipid nanoparticles in mRNA vaccines. View Full-Text
Keywords: mRNA; lipid nanoparticle; ionizable lipid; vaccine; SARS-CoV-2 mRNA; lipid nanoparticle; ionizable lipid; vaccine; SARS-CoV-2
Show Figures

Figure 1

MDPI and ACS Style

Buschmann, M.D.; Carrasco, M.J.; Alishetty, S.; Paige, M.; Alameh, M.G.; Weissman, D. Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines 2021, 9, 65. https://doi.org/10.3390/vaccines9010065

AMA Style

Buschmann MD, Carrasco MJ, Alishetty S, Paige M, Alameh MG, Weissman D. Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines. 2021; 9(1):65. https://doi.org/10.3390/vaccines9010065

Chicago/Turabian Style

Buschmann, Michael D.; Carrasco, Manuel J.; Alishetty, Suman; Paige, Mikell; Alameh, Mohamad G.; Weissman, Drew. 2021. "Nanomaterial Delivery Systems for mRNA Vaccines" Vaccines 9, no. 1: 65. https://doi.org/10.3390/vaccines9010065

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop